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Background: Surveillance of antimicrobial consumption (AMC) is important to address
inappropriate use. AMC data for countries in the European Union (EU) and European
Economic Area (EEA) and Eastern European and Central Asian countries were compared
to provide future guidance.
Methods: Analyses of 2014–2018 data from 30 EU/EEA countries of the European
Surveillance of Antibiotic Consumption network (ESAC-Net) and 15 countries of the WHO
Regional Office for Europe (WHO Europe) AMC Network were conducted using the
Anatomical Therapeutic Chemical (ATC) classification and Defined Daily Dose (DDD)
methodology. Total consumption (DDD per 1000 inhabitants per day) of antibacterials
for systemic use (ATC group J01), relative use (percentages), trends over time, alignment
with the WHO Access, Watch, Reserve (AWaRe) classification, concordance with the
WHO global indicator (60% of total consumption should be Access agents), and
composition of the drug utilization 75% (DU75%) were calculated.
Findings: In 2018, total consumption of antibacterials for systemic use (ATC J01) ranged
from 8.9 to 34.1 DDD per 1000 inhabitants per day (population-weighted mean for ESAC-
Net 20.0, WHO Europe AMC Network 19.6, ESAC-Net Study Group, and WHO Europe
AMC Network Study Group). ESAC-Net countries consumed more penicillins (J01C; 8.7
versus 6.3 DDD per 1000 inhabitants per day), more tetracyclines (J01A; 2.2 versus 1.2),
less cephalosporins (J01D; 2.3 versus 3.8) and less quinolones (J01M; 1.7 versus 3.4) than
WHO Europe AMC Network countries. Between 2014 and 2018, there were statistically
significant reductions in total consumption in eight ESAC-Net countries. In 2018, the
relative population-weighted mean consumption of Access agents was 57.9% for ESAC-
Net and 47.4% for the WHO Europe AMC Network. For each year during 2014–2018,
Edited by:
Olayinka Olabode Ogunleye,










This article was submitted to
Drugs Outcomes Research and
Policies,
a section of the journal
Frontiers in Pharmacology
Received: 08 December 2020
Accepted: 19 March 2021
Published: 17 June 2021
Citation:
Robertson J, Vlahović-Palčevski V,
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14 ESAC-Net and one WHO Europe AMC Network countries met the WHO global
monitoring target of 60% of total consumption being Access agents. DU75% analyses
showed differences in the choices of agents in the two networks.
Interpretation: Although total consumption of antibacterials for systemic use was similar
in the two networks, the composition of agents varied substantially. The greater
consumption of Watch group agents in WHO Europe AMC Network countries
suggests opportunities for improved prescribing. Significant decreases in consumption
in several ESAC-Net countries illustrate the value of sustained actions to address
antimicrobial resistance.
Keywords: antibiotic utilization, antimicrobial medicines consumption, AWaRe classification, cross-national
comparative study, drug utilization 75%, European Surveillance of Antibiotic Consumption Network, Eastern
Europe, Central Asia
INTRODUCTION
Antimicrobial resistance (AMR) is one of the main public health
threats worldwide. It is estimated that each year about 33,000
deaths are attributable to infections with antibiotic resistant
bacteria in the European Union (EU)/European Economic
Area (EEA) (Cassini et al., 2019) and 700,000 globally
(O’Neill, 2016). The Organization for Economic Co-operation
and Development (OECD) predicts that the costs associated with
AMR could increase to US$ 3.5 billion per year if not addressed
(Hofer, 2019).
However, the problem of AMR calls for concerted efforts at
the local, regional and national level as well as close
international cooperation which is not always forthcoming
(Laxminarayan et al., 2020). Ensuring prudent antimicrobial
use is a key priority in an effective response to AMR, as
antimicrobial use exerts ecological pressure on bacteria and
contributes to the emergence and selection of resistant
bacteria. The importance of surveillance of antibiotic
consumption to identify potential overuse, underuse and
inappropriate use is highlighted in the World Health
Organization (WHO) Global Action Plan on AMR (World
Health Organization, 2015), as well as the WHO European
Strategic Action Plan on Antibiotic Resistance (World Health
Organization Regional Office for Europe, 2011) and the
European One Health Action Plan against AMR (European
Commission, 2017).
There are two main networks in the WHO European Region
that collate data on consumption of antimicrobial medicines. The
European Surveillance of Antimicrobial Consumption Network
(ESAC-Net) coordinated by the European Centre for Disease
Prevention and Control (ECDC) collates and analyses data on
antibiotic consumption from 30 countries in the EU/EEA
(European Centre for Disease Prevention and Control, 2020).
Data are available since 1997 and are published on-line and in
annual reports. The WHO Regional Office for Europe (WHO
Europe) Antimicrobial Medicines Consumption (AMC) Network
has been undertaking systematic surveillance of antimicrobial
medicines consumption since 2011 (World Health Organization
Regional Office for Europe, 2020a). AMC data for 2011–2017 for
17 network members have been published (World Health
Organization Regional Office for Europe, 2020b).
Both networks use standardized methods to collect and
analyze data for total AMC, and where possible, disaggregated
to community and hospital AMC. Data collection is based on the
WHO Anatomical Therapeutic Chemical (ATC) classification
system and Defined Daily Dose (DDD) methodology (WHO
ATC/DDD Index, 2018, 2020). Few data have been published
comparing AMC data from the two networks. Data on total
antibiotic consumption in 2011 and 2015 have been published
(Versporten et al., 2014; Robertson et al., 2019). TheWHO global
report on antimicrobial consumption presented combined
European data for 2015 (World Health Organization, 2018).
This study extends these comparisons, comparing data from
30 EU/EEA countries participating in ESAC-Net with data from
15 countries of the WHO Europe AMC Network where
Ministries of Health have agreed on data sharing and
publication. The aim of this study was to examine total
consumption and patterns of consumption of antibiotics, i.e.
antibacterials for systemic use (ATC group J01), in DDD per
1000 inhabitants per day. This is the primary indicator of
antibiotic consumption in countries as defined by the
European Commission and WHO (European Centre for
Disease Prevention and Control, European Food Safety
Authority and European Medicines Agency (ECDC/EFSA/
EMA), 2017a). The relative consumption of oral and
parenteral formulations, the comparative use of WHO
Access, Watch and Reserve (AWaRe) antibiotics, and
concordance with the monitoring indicator that 60% of total
consumption should be Access agents (Sharland et al., 2019;
Klein et al., 2020; World Health Organization, 2020) were
assessed and trends over time examined. In the absence of
indication-linked information on antibiotic use, the WHO
AWaRe classification allows a more detailed analysis of
aggregated data and opportunities for stewardship activities
(Sharland et al., 2019). The AWaRe classification has been
applied to patterns of total antibiotic consumption globally
in 2015 (World Health Organization, 2018), changes over
time between 2000 and 2015 (Klein et al., 2020), analyses of
pediatric antibiotic sales data (Hsia et al., 2019a), published
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studies of antibiotic use in low- and middle-income countries
(Sulis et al., 2020), analyses of national consumption estimates
(McGettigan et al., 2017; Malik and Figueras, 2019; Public
Health Agency of Canada, 2020) and patterns of
consumption in hospitals (Schweickert et al., 2018; Hsia
et al., 2019b).
The combined data presented here provide a pan-European




The data for this study were retrieved from two surveillance networks
in Europe – 30 countries of the ESAC-Net and 15 countries of the
WHO Europe AMCNetwork – for the period 2014 to 2018 (data last
reviewed on October 1, 2020; Figure 1). Details on the methods of
data collection and analysis for both networks have previously been
published (European Centre for Disease Prevention and Control,
2020;World Health Organization Regional Office for Europe, 2020b).
Briefly, data collection follows standardized protocols and only
includes medicines with an assigned ATC code, facilitating
analyses from the main classes (ATC level 1) to individual
substances (ATC level 5). The main analyses presented here are
for the antibacterials for systemic use (ATC group J01). Data on
additional antimicrobials are included in the calculation of the WHO
Access, Watch and Reserve (AWaRe) classification (World Health
Organization, 2019), namely neomycin (A07AA01), streptomycin
(A07AA04), polymyxin B (A07AA05), kanamycin (A07AA08),
vancomycin (A07AA09), colistin (A07AA10), rifamixin
(A07AA11), rifampicin (J04AB02), rifamycin (J04AB03), rifabutin
(J04AB04), metronidazole (P01AB01).
Data Sources
ESAC-Net data are predominantly derived from sales data,
reimbursement data or a combination of these sources
(Supplementary Table S1A). Reimbursement data do not
include consumption of antimicrobials obtained without
prescription and other non-reimbursed courses of therapy
compared to sales data. The extent of consumption not
included when using only reimbursement data may vary by
country (Safrany and Monnet, 2012). ESAC-Net data represent
total coverage of consumption in the countries except for Germany
(85% coverage), the Netherlands (92%) and Luxembourg (91%).
Countries that participate in the WHO Europe AMC Network
mostly rely on import data using customs records and declaration
forms supplemented with sales records from market authorization
holders, local manufacturing estimates, wholesaler records, and in
some cases, commercial data sources (Supplementary Table S1B).
Data represent total consumption estimates except for Kazakhstan
where a commercial data source provides coverage of 80% of
hospital and community sales.
Across both networks, there are countries that have changed
data sources during the study period and/or where data are not
available for all years examined.
Data Analysis and Metrics Reported
Data disaggregated to community and hospital sector consumption
were not available for all studied countries. Consequently, the main
analyses presented here are for total consumption across both sectors
combined. Total numbers of DDDs for each product were aggregated
to give the total number of DDDs at the desired ATC code level and
adjusted for the population size to calculate DDDs per 1000
inhabitants per day. For countries where there was incomplete
coverage, data were extrapolated to estimate 100% consumption to
facilitate comparisons across countries and networks. TheATC/DDD
FIGURE 1 | Total consumption of antibacterials for systemic use (ATC J01) expressed in DDD per 1000 inhabitants per day, by pharmacological subgroup, 2018.
*Member of theWHOEurope AMCNetwork. EU/EEA: population-weightedmean for countries of ESAC-Net.WHO/AMC: population-weightedmean for countries of the
WHO Europe AMC Network. †Countries reported only community data.
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Index 2019 was applied to all years of data to facilitate analysis of
trends over time (WHO Collaborating Centre for Drug Statistics
Methodology, 2020). Eurostat (European Commission 2020a) or
national population estimates were used for EU/EEA countries
and World Bank population estimates (The World Bank, 2020)
were applied to WHO Europe AMC Network countries apart
from Turkey, where estimates were adjusted to take account of the
large refugee population. Patterns of consumption of antibacterials for
systemic use (ATC group J01) by ATC level 3 sub-groups and by
route of administration (oral and parenteral) in 2018 were assessed.
Measures of relative consumption, expressed as a percentage
of total consumption of groups of antimicrobials, were derived for
3rd ATC level group of antibacterials for systemic use, and for the
WHOAWaRe groups of antibiotics (World Health Organization,
2019). The proportion of total consumption that comprised
Access agents was calculated and trends 2014–2018 assessed.
The most frequently used antibiotic substances comprising 75%
of the total consumption (the Drug Utilization 75%, DU75%) were
derived and stratified by route of administration (Zarb et al., 2011).
Summary data were considered for the networks separately
using arithmetic and population-weighted mean estimates. For
each network, a population-weighted estimate of total
consumption was calculated by multiplying DDD per 1000
inhabitants per day for each country with the corresponding
population, then summing the country estimates and finally
dividing the resulting total number of DDDs by the total
population of all participating countries (European Centre for
Disease Prevention and Control, 2019a). Using similar methods,
population-weighted estimates were calculated for the relative
consumption of AWaRe groups of antibiotics and for
components of the DU75%.
Simple linear regression was used to assess trends in antibiotic
consumption for each participating country. The output of the
software used (Excel data analysis module) includes the
regression statistics of a linear regression analysis and the
corresponding analysis of variance (ANOVA) test statistics. To
illustrate changes in antimicrobial consumption rates over time,
we calculated the compound annual growth rate (CAGR) of total
antibiotic consumption for each country, which reflects the
average annual change as a proportion (%) of the
consumption in the starting year. CAGR were estimated for
countries that had five years of available data. P values ≤0.05
were considered statistically significant.
Role of the Funding Source
For ESAC-Net, no specific funding was allocated for this study.
Netherlands Ministry of Health, Welfare, and Sport, and the
German Collaboration Program provide funding for the WHO
Europe AMC Network, but had no role in the study design, data
collection, data analysis, data interpretation, orwriting of themanuscript.
RESULTS
The arithmetic mean and the population-weighted mean total
consumption of antibacterials for systemic use (ATC group J01) in
2018 were similar in the two networks–19.0 and 20.0 DDD per
1000 inhabitants per day, respectively, for ESAC-Net compared to
18.4 and 19.6 DDD per 1000 inhabitants per day, respectively, for
the WHO Europe AMC Network. However, large inter-country
variations were seen among both the 29 ESAC-Net countries
(9.7–34.1 DDD per 1000 inhabitants per day) and the 15 WHO
Europe AMC Network countries (8.9–30.9 DDD per 1000
inhabitants per day) (Figures 1, 2, Supplementary Table S2).
In 2018, the relative consumption of parenteral formulations
varied within and between networks. For the 26 ESAC-Net
countries for which hospital sector data were included in total
consumption of antibacterials for systemic use, parenteral
formulations represented from 3.6 to 23.9% of total consumption
(median 5.9%). For the 15 WHO Europe AMC Network countries,
parenteral formulations comprised between 2.8 and 40.1% (median
13.1%) of total consumption (Supplementary Table S3).
The population-weighted consumption of penicillins (ATC
J01C) differed in the two networks – 8.7 versus 6.3 DDD per
1000 inhabitants per day and representing 43.8 and 31.9% of total
consumption of antibacterials for systemic use for ESAC-Net and
WHO Europe AMC Network countries, respectively
(Supplementary Table S2). Penicillins were the most consumed
subgroup of antibiotics in 28 (97%) of 29 ESAC-Net countries
(range 24.3–65.9% of total consumption) and 9 (67%) of 15 WHO
Europe AMC Network countries (range 14.2–40.2%).
In ESAC-Net countries, there was more consumption of
tetracyclines (J01A; population-consumption 2.2 versus 1.2 DDD
per 1000 inhabitants per day), less consumption of other beta-
lactams, predominantly cephalosporins (J01D; 2.3 versus 3.8 DDD
per 1000 inhabitants per day), and less consumption of quinolone
antibiotics (J01M; 1.7 versus 3.4 DDD per 1000 inhabitants per day)
than in WHO Europe AMC Network countries
(Supplementary Table S2). There was no or very little
reported consumption of amphenicols (J01B) in ESAC-Net
countries and low levels of consumption in only three
countries of the WHO Europe AMC Network: Armenia (0.3
DDD per 1000 inhabitants per day, 2.2% total consumption),
Kazakhstan (0.6 DDD per 1000 inhabitants per day, 3.1%) and
Georgia (0.6 DDD per 1000 inhabitants per day, 2.7%).
Trends, 2014–2018
Table 1 shows the trends in total consumption of antibacterials
for systemic use (ATC group J01) for the years 2014–2018. There
were statistically significant increases in total consumption over
the study period in Greece (2.4%) and Iceland (4.5%). Statistically
significant decreases in total consumption over the study period
were reported in Denmark (CAGR −2.5%), Finland (−5.2%),
Germany (−3.4%), Luxembourg (−1.3%), Netherlands (−1.5%),
Norway (−2.5%), Sweden (−2.9%) and the United Kingdom
(−2.6%). Only one country among the WHO Europe AMC
Network countries had a statistically significant increase or
decrease in total consumption over the study period, namely
Bosnia and Herzegovina (+6.0%).
WHO AWaRe Classification Medicines
The relative consumption of AWaRe antibiotics in 2018 is shown
for the two networks separately in Figure 3, and summarized in
Supplementary Tables S4A and S4B. Access antibiotics
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comprised more than 60% of total consumption in 17 (59%) of
29 ESAC-Net countries and three (20%) of 15WHO Europe AMC
Network countries that provided 2018 data. The population-
weighted mean consumption of Access agents was 57.9% for
ESAC-Net and 47.4% for the WHO Europe AMC Network.
The relative consumption of Watch antibiotics ranged from
13% (Iceland) to 61% (Slovakia) of total consumption for ESAC-
Net countries and from 34% (Bosnia and Herzegovina) to 69%
(Uzbekistan) of total consumption for WHO Europe AMC
Network countries.
Reserve antibiotics represented <1% of total consumption in all
countries included in this analysis. The extent of consumption of
unclassified agents varied and was the highest in Norway and
Poland, representing 24 and 12% of total consumption, respectively.
Trends in the relative consumption of AWaRe agents between
2014 and 2018 are shown in Table 2. According to the WHO
global indicator, i.e. 60% of total consumption should be of Access
agents, 14 (48%) of 29 ESAC-Net countries achieved this target in
each of the five years examined. Only one country in the WHO
Europe AMC Network met this target in all five years.
Drug Utilization 75%
Table 3 (oral agents) and Table 4 (parenteral agents) show the agents
that comprise 75% of total consumption of antibacterials agents for
systemic use (ATC group J01) in each of the participating countries
and networks separately and summarized across each of the networks.
The number of agents constituting the DU75% for oral
substances ranged from 5–9 (median 7) for ESAC-Net
countries and 4–10 (median 8) for the WHO Europe AMC
Network countries (Table 3). Across all countries in the
network combined, the DU75% comprised 10 agents each for
ESAC-Net and the WHO Europe AMC Network.
Oral amoxicillin with enzyme inhibitor (ATC code J01CR02)
was the most consumed oral agent across both networks and
ranked number one in 15 (52%) of 29 ESAC-Net countries and in
five (33%) of 15 WHO Europe AMC Network countries. Oral
amoxicillin alone (J01CA04) was ranked number two overall
across both networks and ranked number one in six (21%)
ESAC-Net countries and six (40%) of WHO Europe AMC
Network countries.
However, there were substantial variations in the distribution of
antibiotics. Three agents, phenoxymethylpenicillin (J01CE02),
flucloxacillin (J01CF05) and pivmecillinam (J01CA08) were not
included in the DU75% of any of the 15 WHO Europe AMC
Network countries. phenoxymethylpenicillin ranked first in
Denmark and Sweden, and second in Norway. Pivmecillinam
ranked second in Denmark, fourth in Norway and sixth in Iceland.
Notably, Watch group agents were included in the DU75% for
all countries. Across all network countries combined, Watch
group agents represented four of nine agents in the DU75%
for ESAC-Net and five of ten agents in the DU75% for the WHO
Europe AMC Network.
FIGURE 2 | Total consumption of antibacterials for systemic use (ATC J01) (expressed as DDD per 1 000 inhabitants per day) for countries of ESAC-Net and the
WHO/Euro AMC Network, 2018. Austria, Iceland and Germany reported only community data.
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TABLE 1 | Trends in total consumption of antibacterials for systemic use (ATC J01), 2014–2018.
*member of the WHO Europe AMC Network.
#CAGR: compound average growth rate. The CAGR was only calculated where there was five years of data (2014–2018) available for the country.
§linear regression not applied due to changes in data sources and/or sectors for which data were reported.
↑↓arrows indicate statistically significant change.
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Across all countries, theWatch group agents azithromycin (ATC
code J01FA10), clarithromycin (J01FA09) and ciprofloxacin
(J01MA02) were included in the DU75% for 30, 25 and 25
countries, respectively. However, the relative rankings of these
agents varied depending on the network. In ESAC-Net,
clarithromycin ranked second for consumption in six (21%) of 29
countries, third in a further four ESAC-Net countries and fourth in
population-weighted estimates. Ciprofloxacin was ranked number
one asmost often consumed oral antibacterial in 3 (20%) of 15WHO
Europe AMC Network countries, second in another country, and
third in population-weighted estimates. This agent ranked no higher
than fourth in any ESAC-Net country. A second quinolone,
levofloxacin (J01MA12), was the most often consumed oral
antibacterial in one country of the WHO Europe AMC Network,
although only ranked seventh in population-weighted estimates.
While parenteral agents represented between 2.8 and 40.1% of
total consumption in 2018, there were 13 different parenteral
agents included in the DU75% for ESAC-Net and five agents for
the WHO Europe AMC Network. Ceftriaxone (J01DD04), a
Watch group agent, ranked as the most often consumed
parenteral agent in 13 (87%) of 15 WHO Europe AMC
Network countries and 7 (24%) of 29 ESAC-Net countries.
DISCUSSION
In 2018, total consumption of antibacterials for systemic use
(ATC group J01) ranged from 8.9 for Azerbaijan to 34.1 DDD per
1000 inhabitants per day for Greece, with similar ranges of
estimates for ESAC-Net and the WHO Europe AMC Network
and similar estimates for the population-weighted mean total
consumption (19.6 and 20.0 DDD per 1000 inhabitants per day,
respectively). However, there were considerable differences in the
absolute and relative consumption of 3rd ATC level groups, with
greater consumption of penicillins and tetracyclines, and less
consumption of cephalosporins and quinolones in ESAC-Net
than in WHO Europe AMC Network countries.
During 2014–2018, there were statistically significant decreases
in total consumption of antibacterials for systemic use (ATC J01)
in eight ESAC-Net countries: Denmark, Finland, Germany,
Luxembourg, the Netherlands, Norway, Sweden and the
United Kingdom. These countries all have longstanding
programmes and commitments toward reducing antibiotic
consumption. WHO Europe AMC Network data were
characterized by more inconsistent patterns, with only one
country showing a significant trend for increased consumption
over 2014–2018. This may reflect the nature of the data collection,
often relying on customs records and data from local
manufacturers as a crude proxy for consumption in these
countries, as well as shorter histories of interventions to tackle
AMR. The latter is, however, starting to change among some of the
WHO Europe AMC Network countries (Robertson et al., 2019)
and may be reflected in future trend analyses.
The observation of similar estimates of total consumption rates
in conjunction with substantially different patterns of AMC
suggests that relying on indicators measuring total consumption
alone is inadequate to assess national performance. More detailed
analyses at the formulation, group and individual agent level are
needed to identify useful targets for national interventions to
improve the use of antibiotics and promote alignment of
clinical practices with international guidance on their
responsible use. This is particularly important if patterns of
FIGURE 3 | Patterns of consumption of antibacterials according to the AWaRe classification of antimicrobial agents, 2018.
AWaRe: Access, Watch and Reserve classification of antimicrobials (World Health Organization 2019).
EU/EEA: population-weighted mean for countries of ESAC-Net.
WHO/AMC: population-weighted mean for countries of the WHO Europe AMC Network.
#Agents included in this analysis: antibacterials for systemic use (J01), neomycin (A07AA01), streptomycin 461 (A07AA04), polymyxin B (A07AA05), kanamycin (A07AA08),
vancomycin (A07AA09), colistin 462 (A07AA10), rifamixin (A07AA11), rifampicin (J04AB02), rifamycin (J04AB03), rifabutin (J04AB04), 463 metronidazole (P01AB01).
§Countries for which hospital sector data were not included.
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TABLE 2 | Countries achieving the target of 60% of total consumption of antibacterials being Access group agents, 2014–2018.
aAgents included in this analysis: antibacterials for systemic use (J01), neomycin (A07AA01), streptomycin (A07AA04), polymyxin B (A07AA05), kanamycin (A07AA08), vancomycin
(A07AA09), colistin (A07AA10), rifamixin (A07AA11), rifampicin (J04AB02), rifamycin (J04AB03), rifabutin (J04AB04), metronidazole (P01AB01).
Country estimates are rounded up.
Green panel identifies countries meeting the WHO global indicator that Access agents should constitute 60% of total antibacterial consumption.
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infectious diseases and AMR, as well as other determinants of
AMC including differences in patient expectations, vary between
countries (Fletcher-Lartey et al., 2016; Sirota et al., 2017; and;
Ritchie et al., 2019). Several disparities reflect the fact that certain
antibiotics, for example, phenoxymethylpenicillin, flucloxacillin
and pivmecillinam, are not registered in some countries. Other
disparities, such as more reliance on parenteral products and
greater use of quinolones in WHO Europe AMC Network than
ESAC-Net countries, aremore likely to reflect prescribing practices
and cultural preferences and are potential targets for interventions
and behavior change.
High levels of consumption ofWatch agents are an obvious target
for interventions including review of clinical guidelines and
prescribing algorithms. Low levels of consumption of Reserve
agents in this study reflect the analysis of data on total
consumption combining community and hospital sectors and
different consumption patterns would be expected in analyses of
hospital data alone. While some classes of agents will be used almost
exclusively in the hospital setting, on average, 90% of overall national
antibiotic consumption across European countries is community
consumption. Disaggregation of data to hospital and community
sectors was not possible in most WHO Europe AMC Network
countries; however, this is an important future development as
countries strengthen and enhance their surveillance capacity and
recognize the value of disaggregated data to inform stewardship
activities in the community and hospital sectors.
Fourteen ESAC-Net countries met WHO’s suggested national
target of 60% of total consumption of antibacterials being derived
from the Access list in each of the five years analyzed. This
suggests that more ambitious targets may be warranted in high-
income countries that already have implemented comprehensive
monitoring and intervention programmes to address AMR. In
contrast, only one country in the WHO Europe AMC Network
achieved this target in each of the five years. The findings in the
high-income countries compare well with Canada where there
was evidence of increasing relative consumption of Access agents
between 2014 and 2018, reaching 67.5% of total consumption in
2018 (Public Health Agency of Canada, 2020).
Despite the expansion of the AWaRe classification in 2019 to
include 180 antibacterials used globally (World Health
TABLE 3 | Antibacterials at substance level (5th ATC group level) that compose the DU75%, oral use, 2018.
Agents included in this analysis: antibacterials for systemic use (J01), neomycin (A07AA01), streptomycin (A07AA04), polymyxin B (A07AA05), kanamycin (A07AA08), vancomycin
(A07AA09), colistin (A07AA10), rifamixin (A07AA11), rifampicin (J04AB02), rifamycin (J04AB03), rifabutin (J04AB04), metronidazole (P01AB01).
The table is sorted according to the number of countries which included the antimicrobial in the DU75%, considering Access (green panel), Watch (yellow panel) and unclassified agents
(gray panel) separately (World Health Organization 2019).
*Numbers of countries which have this agent in DU75%.
EU/EEA population-weighted mean for countries of ESAC-Net.
WHO/AMC population-weighted mean for countries of the WHO Europe AMC Network.
The numbers shown in the table refer to the frequency of use, e.g. 1  most often consumed antimicrobial.
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Organization, 2019), three oral agents, methenamine (J01XX05),
furazidin (J01XE03) and nitroxoline (J01XX07), all used for the
prophylaxis or treatment of urinary tract infections, yet remain
unclassified, but appear in the DU75% for four ESAC-Net
countries and two WHO Europe AMC Network countries.
There is an opportunity for WHO in the future to address the
limitations in the current list and to expand the AWaRe
classification to include antimicrobials that are commonly used
in some countries. Unclassifed agents constituted 24.1% of total
consumption in Norway in 2018, mostly accounted for by
methenamine, which is commonly used for prophylaxis of
urinary tract infections in elderly women and is not
considered to be an AMR-inducing agent (Alberg et al., 2017).
Our estimates of the consumption of unclassified agents differ
from those reported by Klein et al., (2020). These authors used
expert consultations to classify 54 of 233 antibiotics included in
the sales data of the IQVIA database that are currently not
included in the AWaRe classification, leaving only three agents
in their unclassified group.
As noted in other studies, the number of antimicrobials
constituting the DU75% by substance was small (Zarb et al.,
2011) with a median of seven and eight different oral agents in
ESAC-Net andWHOEuropeAMCNetwork countries, respectively.
Linking the DU75% analysis to the AWaRe classification adds
further value, illustrating differences in choices of agents between
countries and networks, their ranking by consumption rates and
identifying potential targets for interventions to improve practices.
The limitations of some of the data have implications for
interpretation of results. Only medicines with an assigned ATC
code and DDD are included in the analyses. Where there are
medicines without codes consumed by the population, estimates
of DDD per 1000 inhabitants per day will be underestimated.
While import records have limitations, they will include over-the-
counter supply of antibacterials without prescription that occurs
in some countries. Differences in data sources can limit some
comparisons. Supply cycles may influence consumption
estimates in some settings while customs records and data
from local manufacturers are a crude proxy for consumption.
TABLE 4 | Antibacterials at substance level (5th ATC group level) that compose the DU75%, parenteral use, 2018.
Agents included in this analysis: antibacterials for systemic use (J01), neomycin (A07AA01), streptomycin (A07AA04), polymyxin B (A07AA05), kanamycin (A07AA08), vancomycin
(A07AA09), colistin (A07AA10), rifamixin (A07AA11), rifampicin (J04AB02), rifamycin (J04AB03), rifabutin (J04AB04), metronidazole (P01AB01).
The table is sorted according to the number of countries which included the antimicrobial in the DU75%, considering Access (green panel), Watch (yellow panel) and unclassified agents
(gray panel) separately (World Health Organization 2019).
*Numbers of countries which have this agent in DU75%.
EU/EEA population-weighted mean for countries of ESAC-Net.
WHO/AMC population-weighted mean for countries of the WHO Europe AMC Network.
The numbers shown in the table refer to the frequency of use, e.g. 1  most often consumed antimicrobial.
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However, in the absence of more robust data, using these sources
allow countries to start the important task of monitoring
antibacterial consumption as part of national efforts to address
AMR. The ATC/DDD methodology provides a common
technical basis for surveillance of antimicrobial consumption.
Where sources remain the same, it is possible to discern trends
more reliably in volumes and patterns of consumption over time.
Despite similar estimates of total consumption of antibacterials
for systemic use (ATC J01) in the Netherlands and in Azerbaijan, 9.7
and 8.9DDDper 1000 inhabitants per day, respectively, the situation
in the two countries is different. Trend analyses demonstrate
statistically significant reductions in total consumption in the
Netherlands but increasing total consumption in Azerbaijan
during 2014–2018. The low starting baseline of consumption
estimates for Azerbaijan in 2014 and variability over the study
period could suggest poor access to antibiotics, incomplete
capture of import and local manufacturing information, the
impact of medicines import cycles, or combinations of these
factors. Nevertheless, this increase in total consumption over time
is consistent with the findings of other studies linking increasing
consumption in low- and middle-income countries to growth in
gross domestic product per capita (Klein et al., 2018), and the quality
of governance in the pharmaceutical sector including regulatory
practices and enforcement of regulations (Rönnerstrand and
Lapuente, 2017). Malik and Bhattacharyya (2019) modeled
complex associations between socio-economic growth, ecology of
infectious disease and antibiotic misuse, particularly through self-
medication, suggesting there are synergistic interactions of these
components feeding back on each other and contributing to AMR.
Similar to the large variations in antibiotic consumption between
countries described by this study and other global analyses (Klein
et al., 2020), considerable differences in the proportion of AMR in
key pathogens have been reported for both EU/EEA countries
(European Centre for Disease Prevention and Control, 2019b)
and non-EU/EEA European countries (World Health
Organization Regional Office for Europe, 2018). Associations
between national antimicrobial consumption rates and national
AMR levels, in both the hospital and community sector, have
been reported for EU/EEA countries (European Centre for
Disease Prevention and Control and European Food Safety
Authority and European Medicines Agency, 2017b), highlighting
the importance of addressing antibiotic consumption as part of
national efforts towards reducing the burden of AMR in Europe
(Wojkowska-Mach et al., 2018). Furthermore, disaggregation of data
to community and hospital sectors facilitates monitoring using
sector-specific metrics for quantifying antibiotic use and assessing
the quality of prescribing (Coenen et al., 2007; de Bie et al., 2016;
Stanic Benic et al., 2018). Hospital antimicrobial stewardship
programmes that generally focus on changes to antimicrobial use
practices have also demonstrated their value in delivering clinical
and economic benefits, with reductions in length of stay a key driver
of cost savings (Nathwani et al., 2019). Community interventions
can be developed, building on existing evidence that communication
skills training and changing patient expectations to receive
antibiotics can lead to significant reductions in antibiotic
prescriptions for viral upper respiratory tract infections (Ritchie
et al., 2019; Strumann et al., 2020).
In conclusion, the development and implementation of effective
national policies to deal with AMR vary across countries in both
ESAC-Net and the WHO Europe AMC Network. Reliable data are
needed to describe patterns of AMC and to monitor the evolution of
AMR. Standardized methods of data collection and analysis and the
application of commonmetrics and indicators facilitate benchmarking
across settings, countries and regions. The quantitative estimates
presented should be considered a starting point for further studies
to understand better the use of these medicines in clinical practice –
this will require further quantitative and qualitative studies in primary
care and hospital sectors at the country level.
The longer history and experience of ESAC-Net provides an
important platform from which to build capacity for monitoring
and evaluation in the WHO Europe AMC Network. Subsequent
cross-national comparisons, especially including quality
measures, can stimulate national and regional discussions and
promote activities and interventions to address problem
practices. Timely data are important if they are to be used to
guide policy developments at the national level. This study
included data for 2018 and captured information on patterns
of antibiotic consumption in countries in Eastern Europe and
Central Asia that are currently not well represented in global sales
databases such as IQVIA (Klein et al., 2020).
Several factors support increased engagement and information
exchange between ESAC-Net and theWHOEuropeAMCNetwork.
Beyond geographic proximity, several members of the WHO
Europe AMC Network are candidate countries for accession to
the EU (European Commission, 2020b). In advance of membership,
these countries must revise their national legislation to be able to
apply the EU’s acquis, the body of common rights and obligations
that are binding on all EU Member States. This will promote
harmonization of procedures for registration of pharmaceutical
products including antibiotics across Europe. Furthermore,
strategic partnerships are a cornerstone of the 2020–2025 WHO
European Programme of Work (World Health Organization
Regional Office for Europe 2020c), and this will facilitate
building on complementary work already being undertaken by
agencies aligned with the European Commission and WHO
Europe. Overall, we believe that this study illustrates the value of
harmonized approaches to data collection and analysis of antibiotic
consumption data that can underpin Europe-wide strategies to
address AMR. In parallel with joint reporting of AMR data from
the European Antimicrobial Resistance Surveillance Network
(EARS-Net) and the WHO Europe Central Asian and European
Surveillance of Antimicrobial Resistance (CAESAR) network, we
plan further reporting on joint ESAC-Net and WHO Europe AMC
surveillance in the future.
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